Hong Kong Local Responsible Person

Companies seeking to sell their medical devices in Hong Kong or IVD products to Hong Kong public hospitals must be listed in the MDACS (Medical Device Administrative Control System) database to meet procurement preference criteria.

Only a Local Responsible Person (LRP), which must be a registered Hong Kong entity, can handle the Listing application and perform various responsibilities such as managing regulatory obligations.

In addition, the Local Responsible Person has responsibility for post-market surveillance (PMS) such as adverse event reporting and ensures labeling compliance. Having an independent third party as an LRP can provide more control over the registration process and greater flexibility in managing distributors. Local Responsible Persons can also facilitate procurement processes for public hospitals, as MDACS-listed products receive preference.

Companies must apply for various classifications and registrations to ensure compliance with local health authorities and market readiness.

Conformity assessment body
Public health

Can I Change My Hong Kong Local Responsible Person?

Yes, appointing a new Hong Kong Local Responsible Person is possible. Manufacturers often consider this when dissatisfied with their current agent, especially if the agent is also their distributor. In such cases, appointing an independent LRP like Cisema can provide greater transparency and control. Additionally, the benefits of appointing an independent Local Responsible Person include enhanced flexibility in distribution strategies and improved compliance with regulatory requirements.

Can I Become My Own Local Responsible Person in the Future?

Yes, this is quite common for manufacturers who grow and wish to establish their own operations in Hong Kong. This local company must satisfy the Hong Kong MDD’s regulatory requirements and is legally responsible for compliance during the entire product life cycle - which includes product registration, post market surveillance, and communication with authorities.

Cisema can remain contracted to help with communications and post market surveillance. Some manufacturers may take on this responsibility themselves once their local operations are ready. Handling these tasks in-house allows for better oversight. However, it requires hiring people who understand the regulatory rules in Hong Kong and any changes to them. Having a Local Responsible Person (LRP) to manage these regulatory obligations is crucial for IVD and medical device companies to ensure compliance and smooth operations.

Our Hong Kong Local Responsible Person Services

As your Local Responsible Person LRP in Hong Kong, we are your single point of contact for all Hong Kong Medical Device Division MDD matters. As we are independent of any distributor, we ensure that you maintain control of your product listings and retain an unconstrained choice of your market access partner(s), giving you full flexibility to adapt as necessary to changes in the market.

Only a Local Responsible Person (LRP), which must be a registered Hong Kong entity, can handle the Listing application and perform various responsibilities such as managing regulatory obligations.

In addition, the Local Responsible Person has responsibility for post-market surveillance (PMS) such as adverse event reporting and ensures labeling compliance. Having an independent third party as an LRP can provide more control over the registration process and greater flexibility in managing distributors. Local Responsible Persons can also facilitate procurement processes for public hospitals, as MDACS-listed products receive preference.

Companies must apply for various classifications and registrations to ensure compliance with local health authorities and market readiness.

Request a Proposal from Our Life Sciences Team about Appointing Us as Your Local Responsible Person in Hong Kong

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

How Does GBA Real World Data Support China NMPA Approvals?

Discover how leveraging Real World Data generated in the Greater Bay Area can accelerate market entry for medical products in China.

July 31, 2026
How Does GBA Real World Data Support China NMPA Approvals?

Cisema Launches a Redesigned Website

Learn about Cisema’s redesigned website with faster performance, clearer navigation and expanded Asia Pacific coverage.

May 6, 2026
Cisema Launches a Redesigned Website
Cisema Logo: Navigating Regulation, Empowering Innovation
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

Hong Kong Medical Device Registration

We assist you through every step of the Hong Kong Medical Device Listing process, ensuring compliance with Medical Device Division requirements. Expedited pathways are available, and we will determine if those are feasible.

Learn more

Hong Kong IVD Registration

We support you through every stage of the Hong Kong IVD Listing process. From classification to handling regulatory requirements, we make the process as smooth as possible.

Learn more

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-market sampling inspections and regular standard changes. Our specialist PMS team means you stay up to date with the many aspects of compliance.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Latest Insights

View More

Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

Circular No. 2/2026 revises prohibited, restricted, colorant, and preservative requirements for cosmetics marketed in Malaysia.

August 20, 2026
Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?

Brands must audit ingredients, suppliers and packaging before January 2028 to ensure compliance with GB 7916-2026.

August 18, 2026
China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?
Scientist in clean modern room inspects cosmetics.

China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Companies can benefit from expanded toxicology data exemptions, simplified cosmetics registration procedures, and more efficient compliance pathways

August 18, 2026
China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories

August 18, 2026
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed

New NCI rules reduce administrative burden, streamline dossiers, and expand opportunities to reuse existing safety data.

August 18, 2026
China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed
This stock photo features a close-up, high-angle shot focusing on a skincare product arrangement set against a light-colored, wood-grain surface.

NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria

Review China's new draft standards for cosmetic cheilitis and contact urticaria before the August 15, 2026, consultation deadline.

August 18, 2026
NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria
Previous
Previous

Contact Our Life Sciences Team

And discover how we can support you as your Local Responsible Person in applying for regulatory approval in Hong Kong.

Request Proposal